no association between the level of latent or activated MMP-2 and the grade of ovarian carcinoma, although all of the carcinomas investigated contained latent and active forms of MMP-2 (Naylor et al, 1994) .
MMP-2 may be involved in two different aspects of ovarian carcinoma spread. Ovarian tumour cells could use MMP-2 to detach from surface epithelia and migrate into the peritoneal cavity (Niedbala et al, 1987) , but they may also use MMP-2 to invade through basement membrane into the ovarian stroma (Campo et al, 1992; Kuwashima et al, 1995) .
Fibroblasts at the invasive edge of ovarian tumours show a striking increase in mRNA for MMP-2 and TIMP-2 (Campo et al, 1992; Autio-Harminen et al, 1993; Naylor et al, 1994) . While ovarian tumour cells in tumour tissue do not contain MMP-2 or TIMP-2 mRNA, latent and activated MMP-2 protein can be detected at their surface (Afzal et al, 1996) . As it is possible that tumour cell lines could utilize fibroblast MMP-2 for invasion (Fishman et al, 1997) , interactions between stromal cells and tumour cells may play an important part in ovarian carcinoma pathology in vivo. In this paper we report that fibroblastcarcinoma cell interactions in vitro result in the stimulation of proMMP-2 and TIMP-2 release by fibroblasts. We also describe a mechanism by which collagen I can induce proMMP-2 activation by tumour-derived, but not normal, fibroblasts.
MATERIALS AND METHODS

Materials
ProMMP-2 and antisera against MMP-2 or TIMP-2 were obtained from TCS Biologicals (Buckingham, UK). Anti-EMMPRIN antibody was a kind gift from Dr Bryan P Toole, Tufts University School of Medicine (Boston, MA, USA). The anti-β 1 integrin antibody was from Gibco (Paisley, UK); rat tail collagen I from Beckton-Dickinson, Bedford, MA, USA and ECL™ reagent was obtained from Amersham (Buckinghamshire, UK). The monoclonal antibodies against MMP-2, MT-MMP-1 or TIMP-2 were purchased from Oncogene Research Products (Cambridge, MA, USA). BB2116 is a synthetic hydroxamate MMP inhibitor which was obtained from British Biotech Pharmaceuticals (Oxford, UK). It was dissolved in dimethyl suphoxide as a 100 mM solution and diluted in phosphate-buffered saline (PBS) to a concentration of 30 µM. The cDNA synthesis 'Ready to Go Kit' was purchased from Pharmacia, (Madison, WI, USA). The PEO1 and PEO14 cells were kindly provided by Dr S Langdon (ICRF, Edinburgh Medical Oncology Unit, UK). SKOV3 cells were obtained from American Type Culture Collection (Rockville, MD, USA).
The human dermal fibroblasts were a gift from Simon Broad (ICRF, London, UK) and the human foreskin fibroblasts were provided by Central Cell Services (ICRF, London, UK). Ovarian tumour-derived fibroblasts were obtained by culture of tumour tissue explants (Noel et al, 1992) and were characterized using collagen I as a positive marker. The polymerase chain reaction (PCR) primers were MT-MMP-1: fCACTGCCTACGAG-AGGAAGG, rTGAATGACCCTCTGGGAGAC; MT-MMP-2: fCGTGTCCTGCTTTACTGCAA, rCTCCAACTGGGCAAA-GAGAG; MT-MMP-3: fCAGGGTGATGGATGGATGGATACC, rCCTTGAGGATGGATCTTGGA; MT-MMP-4: fACGAGGT-CTGCTCATGCA, rCAGGGAGAGGTCATGTTGGT. Other reagents used were supplied by Sigma Chemicals Co (Poole, UK).
Methods
Cell culture and experiments PEO1 and PEO14 cells were cultured in RPMI-1640 and 10% fetal calf serum. SKOV3 cells and fibroblasts were cultured in Dulbecco's modified Eagle medium (DMEM) and 10% fetal calf serum. The human dermal and foreskin fibroblasts were used between passages 5 and 10. In co-culture experiments, a mixture of 2.5 × 10 4 fibroblasts and 12.5 × 10 4 carcinoma cells was plated in 24-well plates (1.88 cm 2 per well) overnight at 37°C and 5% carbon dioxide. Cells were washed four times with 1 ml of serumfree medium and then incubated with 0.5 ml of medium +/-agents for 48 h at 37°C. The medium was then removed and frozen at -20°C. In some experiments, cells were fixed by incubation for 5 min with ice cold 80% methanol. Fixed cells were washed three times with medium before fibroblasts or carcinoma cells were added.
Quantitative gelatin zymography
The methods used here are described in Leber and Balkwill (1997) . Briefly, medium was treated with sample buffer and loaded onto sodium dodecyl sulphate (SDS)-polyacrylamide gels containing 0.12% gelatin. After electrophoresis the gel was incubated in 2.5% Triton X-100 for 1 h, low-salt collagenase buffer for 18 h at 37°C and then simultaneously stained and de-stained. The resulting gel was scanned using the Adobe Photoshop 4.0 software package. The NIH 1.58 software package was used to quantitate changes in gelatin concentration. The gelatinolytic activity of unknown samples was calibrated relative to a fixed amount of standard proMMP-2.
Triton X-114 extraction of proteins Hydrophobic proteins were separated from aqueous proteins by Triton X-114 at 37°C (Bordier, 1981) . A total of 2 × 10 6 fibroblasts per 25 cm 2 well were washed four times in ice cold serum-free medium and 1 ml of ice cold 1.5% Triton X-114 TBS (50 mM TrisHCl, pH 7.4, 150 mM sodium chloride, 2 mM Mg 2+ , 5 mM Ca 2+ ) was added for 1 h at 4°C. Cells were scraped using a rubber policeman and the detergent mixture was spun at 13 000 g. The supernatant was incubated at 37°C for 5 min and centrifuged 13 000 g for 2 min. The lower detergent phase, containing hydrophobic protein, was separated from the upper aqueous phase, containing hydrophilic proteins. The detergent phase was subjected to three more extractions. The aqueous and detergent phases were analysed for gelatinase activity as described (Lewalle et al, 1995) .
ProMMP-2 processing by Triton X-114 membrane protein extracts In order to detect proMMP-2 processing activity by fibroblast membranes, fibroblasts (2 × 10 6 ) were treated with Triton X-114 and 50 µl detergent extract was mixed with 50 µl of TBS, containing 0.02% sodium azide and proMMP-2 (10 ng). ProMMP-2 was also incubated with detergent alone as a control. The reaction mixture was incubated for 48 h at 37°C and the aqueous phase was analysed by gelatin zymography (Lewalle et al, 1995) .
Western blotting
Protein in supernatant from the co-culture experiments was precipitated with acetone, run on an SDS-polyacrylamide gel and blotted onto a nitrocellulose membrane. The membrane was blocked by 5% milk powder and incubated with specific anti-TIMP-2 or anti-MMP-2 antisera. The blot was treated with HRP-linked mouse or rabbit IgG and analysed using the ECL™ system. In some cases, 0.5 × 10 6 carcinoma cells or fibroblasts were washed and treated with 1.0 ml of 2.5% v/v Triton X-114 for 1 h at 4°C. The protein was extracted from the detergent using chloroform-methanol (Bordier, 1981) and analysed as described above.
Reverse transcription (RT)-PCR RNA was extracted from cells using the TRI™-reagent, digested by DNAse and converted to cDNA using a Pharmacia 'Ready To Go Kit'. cDNA was amplified using specific sets of primers and conditions (Liabakk et al, 1996) .
RESULTS
MMP-2 and TIMP-2 release
Studies of ovarian carcinoma tissue have shown that it consists of nests of tumour cells surrounded by a stroma of fibroblast-like cells (Naylor et al, 1994) . Co-culture of dermal fibroblasts and ovarian carcinoma cell lines resulted in similar structures to those seen in vivo with small islands of tumour cells surrounded by sheets of fibroblasts ( Figure 1 ).
We used dermal fibroblasts to determine if co-culture of normal fibroblasts with tumour cells could enhance proMMP-2 release into the culture medium. When cultured alone, dermal fibroblasts released proMMP-2 as measured by zymography ( Figure 2A ). Ovarian carcinoma cell lines also released small amounts of proMMP-2 which varied with cell line (Figure 2A ). In co-culture experiments with dermal fibroblasts and the ovarian tumour cell lines PEO1, PEO14 or SKOV3, a ratio of 1:5 was chosen because at the leading edge of tumour tissue there is an excess of tumour cells to fibroblasts (Naylor et al, 1994) . A two-to eightfold enhanced release of proMMP-2 was found in such co-cultures ( Figure 2A ). This enhancement of proMMP-2 release during co-culture was quantified and found to be significant, P < 0.001 ( Figure 2B ).
We then isolated fibroblasts from ovarian tumours and co-cultured them with tumour cells to determine if the tumour fibroblasts behaved in a similar way to normal fibroblasts in co-culture. Coculture of ovarian carcinoma cell lines with three different batches of fibroblasts derived from ovarian carcinomas resulted in similar structures to those described in Figure 1 and also resulted in a significant stimulation of proMMP-2 release, P < 0.05 ( Figure 2C ). The higher basal release of proMMP-2 from tumour fibroblasts resulted in a lower fold increase of proMMP-2 release compared to that found in dermal fibroblast co-cultures ( Figure 2B , C).
Western blotting of protein from cultured supernatants with MMP-2 antisera confirmed the results seen with gelatin zymography ( Figure 3) ; co-culture of dermal fibroblasts and the ovarian carcinoma cell lines enhanced the release of proMMP-2 into the culture media (two-to sixfold increase in three independent experiments). The level of TIMP-2 immunoreactivity in culture medium from co-cultures was also stimulated by a similar degree ( Figure 3 ).
Conditioned medium from the carcinoma cell lines PEO1, PEO14 and SKOV3 did not enhance the release of proMMP-2 from dermal fibroblasts and also had no effect on fibroblast proliferation (data not shown). However, culture of dermal fibroblasts and fixed carcinoma cells resulted in an significant increase in proMMP-2 release from dermal fibroblasts, P < 0.01 (Figure 4) . Culture of tumour fibroblasts and fixed carcinoma cells also stimulated proMMP-2 release, but fixed fibroblast cell membranes did not enhance proMMP-2 release from the carcinoma cells (data not shown).
ProMMP-2 activation
Co-culture of fibroblasts and ovarian carcinoma cell lines did not result in significant activation of proMMP-2 (Figures 2A and 3) . A trace amount of the activated 62 kDa form of MMP-2 could be detected in the medium from co-cultures, but it was < 1% of total MMP-2 activity. However, the activated form of MMP-2 is readily detected in ovarian carcinoma tissue (Naylor et al, 1994; Noel et al, 1994; Ito et al, 1995) . We therefore investigated the expression of MT-MMP-type enzymes in fibroblast and carcinoma cells, and the ability of cell membranes to activate proMMP-2. Figure 2 Effect of co-culture of ovarian carcinoma cell lines PEO1, PEO14 and SKOV-3 with dermal or tumour fibroblasts on the release of MMP-2 into the culture medium. (A) Fibroblasts, carcinoma cells and carcinoma and fibroblast cells were incubated overnight in culture medium + serum. Cells were then washed and incubated for 48 h in serum-free medium. The resulting conditioned medium was analysed by gelatin zymography. ProMMP-2 standard (1), proMMP-2 and 62-kDa MMP-2 standards (2), conditioned medium from fibroblasts (3), PEO1 (4), PEO14 (5), SKOV-3 (6), fibroblasts + PEO1 (7), fibroblasts + PEO14 (8) and fibroblasts + SKOV-3 (9). These results are representative of three separate experiments.
(B) Culture medium from dermal fibroblasts (HDF), fibroblasts + PEO1, fibroblasts + PEO14, and fibroblasts + SKOV-3, were analysed by quantitative gelatin zymography. The proMMP-2 release from the carcinoma cell lines alone was subtracted from the co-culture values. The results are means ± s.d. from four independent experiments (* represents P < 0.001).
(C) Culture medium from three different batches of ovarian tumour fibroblasts (OF) with the carcinoma cell line PEO1 was analysed by quantitative zymography. The MMP-2 release from PEO1 cells alone was subtracted from the co-culture value. The results are means ± s.d. for two independent experiments. * represents P < 0.05 and **P < 0.01
Membrane-bound metalloproteinase activators of proMMP-2 Using RT-PCR we found that fibroblasts (both dermal and tumour), PEO14, SKOV3, but not PEO1, ovarian cells all expressed MT-MMP-1 mRNA. RT-PCR analysis of MT-MMP-1, -2, -3, and -4 revealed no qualitative difference in the expression profile for the dermal and tumour fibroblasts. The fibroblasts, PEO14 and SKOV3 cells also had a low level of MT-MMP-1 protein in their membranes. To elevate the level of membrane MT-MMP-1 (both the 63 and the activated 60 kDa forms) we treated tumour fibroblasts with 50 µg ml -1 concanavalin A (Lohi et al, 1996) . However, this did not result in the activation of extracellular proMMP-2 by the tumour fibroblasts ( Figure 5A ). Incubation of proMMP-2 with a membrane protein extract of tumour fibroblasts (detergent phase from Triton X-114-treated tumour fibroblasts) converted the 72 kDa proMMP-2 to the 64 kDa form of MMP-2. This activation of MMP-2 was blocked by an inhibitor of matrix metalloproteinases, BB2116 (30 µM), suggesting that a MMP-type enzyme was involved in proMMP-2 processing ( Figure 5B ). As the tumour fibroblasts released TIMP-2 as well as proMMP-2 (data not shown), we incubated MMP-2 complexed with TIMP-2 with the detergent phase from Triton X-114-extracted tumour fibroblasts. No activation of proMMP-2 was seen under these conditions ( Figure 5B ). The detergent phase from Triton X-114-extracted PEO14 and SKOV3, but not PEO1, cells was also able to activate proMMP-2 and this activation of MMP-2 was blocked by 30 µM BB2116 (data not shown).
Taken together, these results suggest that MT-MMP-type enzymes in the membrane of both tumour cells and fibroblasts can activate proMMP-2, but in co-culture their action is blocked, most likely by TIMP-2. We therefore investigated factors in the extracellular environment of tumours which could stimulate proMMP-2 activation and account for the presence of active MMP-2 in ovarian cancer biopsies. One potential candidate was collagen I, which is a major component of ovarian carcinoma tissue (Zhu et al, 1994) . Previous studies showed that culture of normal fibroblasts in collagen gels results in proMMP-2 activation (Azzam and Thompson, 1992; Seltzer et al, 1994; Gilles et al, 1997) .
Collagen I treatment of fibroblasts
Treatment of normal dermal fibroblasts with soluble collagen I (100 µg ml -1 ) did not increase activation of proMMP-2 ( Figure 6A ). However, incubation of three different batches of tumour fibroblasts with collagen I (100 µg ml -1 ) resulted in the appearance of the fully activated 62 kDa form of MMP-2 in the cell culture medium ( Figure 6A shows a typical result). A faint gelatinolytic band of 64 kDa could also be detected between the 72 and 62 kDa forms of MMP-2 ( Figure 6A ). BB-2116 (30 µM) blocked the activation of proMMP-2 by tumour fibroblasts in the presence of collagen I ( Figure 6A ). The amount of 62 kDa MMP-2 detected in the culture medium of collagen I-treated cells was increased by 10 ± 2-fold in three experiments. This activated form of MMP-2 could also be detected by Western blotting with specific MMP-2 antiserum (data not shown). The effects of collagen I (4-100 µg ml -1 ) on proMMP-2 activation were dose-dependent ( Figure 6B ). The response of tumour fibroblasts to collagen I was only present for the first few passages after isolation (data not shown).
The association of active MMP-2 with cell membranes We next looked for the presence of active MMP-2 in the membranes of collagen I and concanavalin A-treated tumour fibroblasts. Tumour fibroblasts were incubated with medium alone, collagen I or concanavalin A. Fibroblasts were treated with Triton X-114 and the detergent phase (containing membrane proteins) was analysed for gelatinase activity. The detergent phase from fibroblasts treated with medium alone contained no gelatinase activity. However, the detergent phase from collagen I-treated cells contained a 62 kDa band, whereas the detergent phase from concanavalin A-treated cells contained only a 72 kDa gelatinase band (Figure 7 ).
Integrin-mediated activation of MMP-2
Collagen I can interact with integrin collagen receptors such as α 2 β 1 and α 1 β 1 . Treatment of tumour fibroblasts with specific anti-β 1 integrin antibody (10 µg ml -1 ) also resulted in the activation of proMMP-2 but only the 64 kDa form of MMP-2 could be detected; BB-2116 (30 µM) blocked proMMP-2 activation by both collagen 1 and anti-β 1 integrin antibody (Figure 8) . Treatment of normal dermal fibroblasts with the anti-β 1 integrin did not result in proMMP-2 activation (Figure 8 ).
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DISCUSSION
In this study, an in vitro co-culture system was used to investigate the mechanisms by which ovarian carcinoma cells stimulate MMP-2 release and activation by fibroblasts. Culture of ovarian carcinoma cells with normal dermal fibroblasts or ovarian tumour fibroblasts resulted in a stimulation of proMMP-2 release into the medium. The stimulation of proMMP-2 release, seen when tumour fibroblasts were cultured with ovarian cancer cells, was lower than that seen with dermal fibroblasts, probably because of higher basal release of proMMP-2 from tumour fibroblasts.
In co-cultures of normal fibroblasts and carcinoma cell lines, TIMP-2 release was also enhanced. The stimulation of proMMP-2 and TIMP-2 release from co-cultures may suggest that the release of these proteins is co-ordinately regulated. This observation is also consistent with the lack of proMMP-2 activation found in co-cultures since TIMP-2 inhibits MT-MMP-1 mediated MMP-2 activation.
Cultured ovarian carcinoma cells or cell lines release both MMP-2 and TIMP-2 (Moser et al, 1994) . On the basis of in vitro studies it has been proposed that ovarian carcinoma cells may produce MMP-2 in vivo (Fishman et al, 1997; Westerlund et al, 1997) . However, in ovarian cancer biopsies, MMP-2 and TIMP-2 mRNAs localize to the stroma. Epithelial carcinoma cell production of these molecules was not detected (Naylor et al, 1994) . This suggests that production of proMMP-2 and TIMP-2 by cultured carcinoma cells may be an adaptation to in vitro culture conditions.
Culture of fibroblasts with fixed carcinoma cells indicates that cell-cell contact plays an important part in the enhancement of proMMP-2 release seen in co-cultures. This is in agreement with the in vivo data where only the fibroblasts close to, or in contact with, carcinoma cells have elevated mRNA for MMP-2 and TIMP-2 (Naylor et al, 1994) . The nature of the membrane factor(s) that stimulates proMMP-2 and TIMP-2 release is unknown. EMMPRIN has been proposed as a regulator of MMP-2 release from fibroblasts (Kataoka et al, 1993) and, although this protein could be detected in PEO1 and PEO14 membranes, it could not be detected in SKOV3 cell membranes, yet all three stimulated proMMP-2 release (data not shown).
Both tumour fibroblasts and carcinoma cells express MT-MMP-1 protein (Fishman et al, 1997) and we confirmed this in our study. MT-MMP-1 mRNA is expressed in stromal fibroblast-like cells close to tumour cells in tumour tissue (Okada et al, 1995; Ohtani et al, 1996; Ueno et al, 1997) . It has been proposed that MT-MMP-1 is responsible for the activation of proMMP-2 in ovarian carcinoma tissue (Fishman et al, 1997) . However, co-culture of ovarian carcinoma cells and normal or tumour fibroblasts did not result in the activation of MMP-2, probably because extracellular TIMP-2 blocked proMMP-2 activation. Even when the amount of MT-MMP-1 in tumour fibroblasts was increased by concanavalin A treatment, no significant activation of MMP-2 could be seen, in agreement with a recent study on primary human fibroblasts (Lohi et al, 1996) . Hence the expression of MT-MMP-1 protein does not always correlate with MMP-2 activation. The ovarian carcinoma microenvironment is rich in TIMPs (Naylor et al, 1994; Tamamkoshi et al, 1995; Kikkawa et al, 1997) and these inhibitors might be predicted to block the activity of MT-MMP-type enzymes.
We have found that levels of collagen I as low as 4 µg ml -1 can stimulate the activation of proMMP-2 by tumour fibroblasts, even in the presence of TIMPs. Normal fibroblasts did not display this responsiveness to similar doses of collagen I. Incubation of normal fibroblasts or invasive breast cancer cells in collagen I gels (containing 0.5-1 mg ml -1 of collagen I), results in gross morphological changes and the intracellular activation of proMMP-2 by a metalloproteinase-like enzyme, but no change in TIMP-2 release (Seltzer et al, 1994; Gilles et al, 1997; Lee et al, 1997) . Gilles et al (1997) also reported that three dimensional collagen gel culture up-regulated MT-MMP-1. However, at the lower collagen concentrations used in our study, the tumour-derived fibroblasts seem to exhibit an enhanced responsiveness to collagen.
It is likely that collagen I is acting through the α 2 β 1 or α 1 β 1 receptors on the tumour-derived fibroblasts to stimulate proMMP-2 activation to the 62 kDa form of MMP-2. Anti-β 1 integrin antibody induced tumour, but not normal, fibroblasts to activate proMMP-2 into the 64 kDa form of MMP-2. This result suggests that the β 1 integrin subunit is involved in the differential response of tumour fibroblasts to collagen I; this could occur by an up-regulation of the β 1 subunit and/or integrins or an enhanced affinity of β 1 integrin for collagen I. It is of interest that treatment of rhabdomyosarcoma cells with anti-α 3 and anti-α 2 integrin antibodies increased their ability to activate MMP-2, and also increased proMMP-2 secretion and invasiveness through matrigel (Kubota et al, 1997) .
There are at least three possible mechanisms by which collagen 1 treatment leads to proMMP-2 activation: collagen I could induce the expression of a metalloproteinase or metalloproteinase activator, it may reduce TIMP-2 levels, or it may relocalize MT-MMP-1 to specific cellular sites. At the site of invasion, β 1 integrin may possibly interact with MT-MMP-1. We also have preliminary data that collagen 1 does not up-regulate metalloprotease activity in tumour fibroblasts, again favouring the third hypothesis.
In conclusion, we have found that fibroblast-carcinoma cell interaction in vitro results in the stimulation of proMMP-2 and TIMP-2 release by fibroblasts. This corresponds to our in vivo observations of MMP-2 and TIMP-2 mRNA expression and localization (Naylor et al, 1994) . We have also found that ovarian tumour-derived fibroblasts have a novel responsiveness to collagen I with respect to proMMP-2 activation. Collagen I stimulation of proMMP-2 activation by tumour-derived fibroblasts appears to involve the ligation of the β 1 integrin and provides a mechanism by which ovarian tumours could activate MMP-2, despite the presence of TIMPs. The binding of this activated MMP-2 by receptors in the invadopodia of invasive cells, provides a temporal window of opportunity for the utilization of active MMP-2 in cell migration and invasion.
